The Citizens Commission on Human Rights (CCHR) is urging consumers to scrutinize psychotropic medication labels for warnings about suicide, aggression, and homicidal ideation, and to demand that prescribing physicians explain these risks, regardless of how rare they may be listed. This call follows recent news reports of violent crimes allegedly linked to prescribed antidepressants, stimulants, or other psychiatric drugs, underscoring the need for patients to be fully informed about potential adverse effects.
CCHR's ongoing campaign has highlighted documented side effects such as agitation, aggression, and suicidal thoughts associated with certain psychiatric medications. Regulatory bodies in the U.S. and abroad have responded by mandating warnings in drug labeling. However, CCHR argues that a buried warning is insufficient. Jan Eastgate, president of CCHR International, stated, "A rare warning buried in a package insert is not the same as a doctor explaining the risk to a patient. Listing a side effect as 'rare' does not establish that the patient was told about it, understood it, or agreed to take that risk. Meaningful informed consent requires meaningful disclosure and prescriber accountability."
The legal and psychiatric communities are also grappling with these issues. Psychiatric Times recently published an article titled "Psychiatry on Trial: Are Psychiatrists Responsible for Their Patients' Criminal Behavior?" examining a high-profile murder case where psychiatric polypharmacy was argued as a contributing factor. The journal noted that "a good portion of the public and the media appear to support the defense theory," placing mental health providers under scrutiny and potentially putting psychiatry itself on trial.
The legal doctrine of involuntary intoxication may apply in cases where prescribed drugs are alleged to induce violent behavior, depending on whether the drug was taken as prescribed and whether the individual knew of the potential effects. Eastgate emphasized, "A judge allowing a jury to hear evidence about prescription drugs is not the same as a physician warning a patient before the first dose. The existence of a warning in drug labeling does not, by itself, establish that an individual patient was adequately informed."
This concern is not new. In a December 2005 article on psychopharmacology liability, Psychiatric Times discussed psychiatrists' duties following the FDA's 2004 public health advisory on antidepressants, which cited reports of anxiety, agitation, and hostility in both adults and children. The FDA subsequently mandated boxed warnings on suicidality for antidepressants, later expanded to young adults.
CCHR's analysis reveals a dramatic increase in regulatory warnings related to violence: since 2004, there have been 57 warnings or safety notices involving violence, aggression, or hostility, compared to just five in 2004—a 1,040% rise. Thirteen of these notices specifically mention homicidal ideation. For instance, homicidal ideation was added to venlafaxine labeling in 2005, and in 2009, the FDA required a boxed warning for bupropion products citing hostility and homicidal ideation. In 2023, the FDA mandated class-wide warnings for stimulants noting anxiety, psychosis, and suicidal or homicidal ideation with misuse. Esketamine labeling advises patients to seek help for sudden mood or behavioral changes, including aggression, and aripiprazole lists homicidal ideation among rare adverse reactions.
Despite these label changes, CCHR contends that printing a warning does not ensure patient awareness or understanding. This issue has even entered public policy, with a 2026 Tennessee law requiring toxicology testing after violent incidents. CCHR advocates for such legislation nationwide.
Eastgate concluded, "Drug labeling now contains warnings that consumers have a right to know about. While not all individuals will experience these effects, they should read the warnings and ask questions before agreeing to treatment. Prescribers should explain potentially serious risks—including those considered rare—and document that the patient was fully informed."
Ultimately, CCHR stresses that the issue is not whether every patient will experience these reactions, but whether patients are adequately informed when regulators have identified serious behavioral risks. Patients should not abruptly stop psychiatric medications; any changes should be managed medically.
CCHR, established in 1969 by the Church of Scientology and Dr. Thomas Szasz, remains committed to transparent disclosure of known drug risks and prescriber accountability as fundamental to informed consent.
